夫西地酸治疗瘤型麻风的临床试验。
Clinical trial of fusidic acid for lepromatous leprosy.
作者信息
Franzblau S G, Chan G P, Garcia-Ignacio B G, Chavez V E, Livelo J B, Jimenez C L, Parrilla M L, Calvo R F, Williams D L, Gillis T P
机构信息
Laboratory Research Branch, Gillis W. Long Hansen's Disease Center, Louisiana State University, Baton Rouge 70894.
出版信息
Antimicrob Agents Chemother. 1994 Jul;38(7):1651-4. doi: 10.1128/AAC.38.7.1651.
Fusidic acid was assessed for antileprosy activity in nine lepromatous leprosy patients. Patients received fusidic acid at either 500 mg/day for 12 weeks or 750 mg/day for 4 weeks followed by 500 mg/day for 8 weeks. All patients showed time-dependent clinical improvement and decreases in bacillary morphological index, radiorespirometric activity and PCR signal, and in serum phenolic glycolipid I. Fusidic acid appears to be a weakly bactericidal antileprosy agent which may have a role in the multidrug treatment of leprosy pending an evaluation of lepra-reaction-suppressive activity.
对9例瘤型麻风患者评估了夫西地酸的抗麻风活性。患者接受夫西地酸治疗，剂量为每日500毫克，持续12周；或每日750毫克，持续4周，随后每日500毫克，持续8周。所有患者均出现了与时间相关的临床改善，同时细菌形态学指数、放射呼吸测定活性、PCR信号以及血清酚糖脂I均降低。夫西地酸似乎是一种弱杀菌性抗麻风药，在对其麻风反应抑制活性进行评估之前，可能在麻风病的联合化疗中发挥作用。
Zotero 插件